JW Pharmaceutical Corp (001065) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.132x

Based on the latest financial reports, JW Pharmaceutical Corp (001065) has a cash flow conversion efficiency ratio of 0.132x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩46.92 Billion ≈ $31.79 Million USD) by net assets (₩354.10 Billion ≈ $239.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check JW Pharmaceutical Corp strategic asset allocation index to assess the company's strategic physical and investment asset allocation.

JW Pharmaceutical Corp - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how JW Pharmaceutical Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. See 001065 book value for net asset value and shareholders' equity analysis.

JW Pharmaceutical Corp Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of JW Pharmaceutical Corp ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Beijing New Universal Science and Technology Co Ltd SHE:300472	0.155x
CapsoVision, Inc. Common Stock NASDAQ:CV	-0.580x
IVF Hartmann Holding AG SW:VBSN	0.014x
Banvit Bandirma Vitaminli Yem Sanayi AS IS:BANVT	-0.067x
Xinlong Holding Group Co Ltd SHE:000955	-0.035x
AB Traction ST:TRAC-B	0.030x
Sphera Franchise Group SA MiFID Eligible Security RO:SFG	0.689x
VT GMP Co.Ltd KQ:018290	-0.043x

Annual Cash Flow Conversion Efficiency for JW Pharmaceutical Corp (2014–2024)

The table below shows the annual cash flow conversion efficiency of JW Pharmaceutical Corp from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see 001065 market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩329.49 Billion ≈ $223.29 Million	₩79.39 Billion ≈ $53.80 Million	0.241x	-26.62%
2023-12-31	₩265.44 Billion ≈ $179.89 Million	₩87.16 Billion ≈ $59.07 Million	0.328x	+30.59%
2022-12-31	₩225.76 Billion ≈ $152.99 Million	₩56.76 Billion ≈ $38.47 Million	0.251x	+161.57%
2021-12-31	₩188.54 Billion ≈ $127.77 Million	₩18.12 Billion ≈ $12.28 Million	0.096x	-68.37%
2020-12-31	₩207.47 Billion ≈ $140.60 Million	₩63.05 Billion ≈ $42.73 Million	0.304x	+25.93%
2019-12-31	₩230.09 Billion ≈ $155.93 Million	₩55.53 Billion ≈ $37.63 Million	0.241x	+20.47%
2018-12-31	₩260.11 Billion ≈ $176.27 Million	₩52.11 Billion ≈ $35.31 Million	0.200x	+62.17%
2017-12-31	₩270.78 Billion ≈ $183.50 Million	₩33.45 Billion ≈ $22.67 Million	0.124x	+406.54%
2016-12-31	₩276.31 Billion ≈ $187.25 Million	₩6.74 Billion ≈ $4.57 Million	0.024x	+231.67%
2015-12-31	₩225.41 Billion ≈ $152.75 Million	₩-4.17 Billion ≈ $-2.83 Million	-0.019x	-155.99%
2014-12-31	₩220.02 Billion ≈ $149.11 Million	₩7.28 Billion ≈ $4.93 Million	0.033x	--

About JW Pharmaceutical Corp

KO:001065 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$335.70 Million

₩495.37 Billion KRW

Market Cap Rank

#14498 Global

#479 in Korea

Share Price

₩24650.00

Change (1 day)

-2.18%

52-Week Range

₩24650.00 - ₩30000.00

All Time High

₩88605.96